40 -1 (75) 2025 - Kim G.S., Agababyan I.R. - A METHOD OF NON-DRUG THERAPY FOR NON-ALCOHOLIC FATTY LIVER DISEASE

A METHOD OF NON-DRUG THERAPY FOR NON-ALCOHOLIC FATTY LIVER DISEASE

Kim G.S. - Samarkand State Medical University

Agababyan I.R. - Samarkand State Medical University

Ismoilova Y.A. - Samarkand State Medical University

Resume

In recent years, many treatments for non-alcoholic liver disease have emerged, including non-drug treatments, GLP-1, NGCT-2, and bariatric surgery for weight loss, all aimed at preventing or reducing liver fibrosis, the risk of cirrhosis, hepatocellular carcinoma, and development of cardiovascular complications, type 2 diabetes mellitus [3,4]. Currently, there are several methods of non-drug correction of NAFLD: low-carbohydrate diet, hypocaloric diet, intermittent fasting, Mediterranean diet. Each diet works in its own way with a positive effect [1,6]. And the proposed nutrition program, the diet of which includes natural proteins and vegetables, drinking regimen, and physical activity, is distinguished by the fact that in order to penetrate proteins into liver cells and displace fatty inclusions, they use the method and time of preparing proteins while preserving the protein structure; through the use of drinking regime, the use of salt and sugar [8].

Key words: non-alcoholic fatty liver disease, steatosis, visceral fat.

First page

246

Last page

252

For citation:Kim G.S., Agababyan I.R., Ismoilova Y.A. - A METHOD OF NON-DRUG THERAPY FOR NON-ALCOHOLIC FATTY LIVER DISEASE//New Day in Medicine 1(75)2025 246-252 https://https://newdayworldmedicine.com/en/new_day_medicine/1-75-2025

List of References

  1. Agababyan I., Soliyeva S., Ismoilova Y. Condition of coronary arteries and change of lipid profile in coronary heart disease //Annals of the Romanian Society for Cell Biology. 2021; 207-213 p.
  2. Agababyan I. R., Pulatova K.S., and M. S. Rofeev. "Metabolic syndrome as one of the main factors of arterial hypertension development." //Achievement of science and education 2019;10:51.а
  3. Benсe K. K., Birnbaum M. J. Metaboliс drivers of non-alсoholiс fatty liver disease //Moleсular metabolism. 2021;50:101-143.
  4. Rubenovna A. I. et al. Analysis of the effect of food stereotypes on disease in liver circuit disease //Asian journal of pharmaceutical and biological research. 2022;11:2.
  5. Rubenovna A.I., Safronovna K.G., Sergeevna X.D., Alexandrovna K.N. (2024). Изучение компонентного состава организма на ранней стадии неалкогольной жировой болезни печени. //Journal of biomediсine and praсtiсe 2024;9(1).
  6. Rubеnоvnа А.I. еt аl. Изучение компонентного состава организма на ранней стадии неалкогольной жировой болезни печени //Jоurnаl оf biоmеdiсinе аnd prасtiсе. 2024;9(1).
  7. Younossi Z.M. et al. Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease //Journal of hepatology. 2024;80(5):694-701.
  8. Younossi Z.M. et al. Economic and clinical burden of nonalcoholic steatohepatitis in patients with type 2 diabetes in the US //Diabetes care. 2020;43(2):283-289.
  9. Агабабян И. Р., Исмоилова Ю. А., Султонова Н. Р. Железодефицитная анемия у больных с постинфарктным кардиосклерозом //Евразийский журнал медицинских и естественных наук. 2022;2(5):249-252.
  10. Агабабян И.Р., Садыкова Ш.Ш. (2022). Выявление нарушений скорости клубочковой фильтрации в зависимости от степени ожирения (обзор литературы). //Журнал репродуктивного здоровья и уро-нефрологических исследований 2022;3(2).
  11. Ризаев Ж.А., Агабабян И.Р., Исмоилова Ю.А. "Мировой опыт работы специализированных клиник по лечению больных с хронической сердечной недостаточностью. //Вестник врача 2021;3:100.
  12. Сhаlаsаni N, Younossi Z. M. et al. Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis //Hepatology. 2018;68(1):349-360.

    file

    download